Mechanism of Action.
SS-31 (elamipretide) is a cell-permeable tetrapeptide with alternating aromatic-cationic motifs (D-Arg-Dmt-Lys-Phe-NH2) that enable selective concentration in the inner mitochondrial membrane at over 1,000-fold enrichment relative to cytoplasm. It binds to cardiolipin, a phospholipid unique to the inner mitochondrial membrane that is essential for cristae structure and electron transport chain (ETC) organization. By stabilizing cardiolipin-cytochrome c interactions, SS-31 optimizes electron transfer between Complex III and Complex IV, reducing electron leak and superoxide generation. This improves ATP synthesis efficiency while simultaneously reducing oxidative stress. SS-31 also protects cardiolipin from peroxidation, preserving mitochondrial membrane integrity during stress.
Research Summary.
Elamipretide has been studied in Phase 2 and 3 clinical trials for primary mitochondrial diseases, heart failure, and age-related mitochondrial dysfunction. In Barth syndrome (a genetic cardiolipin deficiency), Phase 2 data showed improvements in the 6-minute walk test and cardiac function. The TAZPOWER Phase 3 trial assessed elamipretide in Barth syndrome patients. In heart failure trials (EMBRACE-STEMI and PROGRESS-HF), elamipretide showed trends toward improved cardiac function and reduced infarct size. Preclinical aging research has demonstrated restoration of age-related mitochondrial dysfunction, improved cardiac function in aged mice, and reversal of age-related skeletal muscle decline. The compound represents the most advanced mitochondria-targeted peptide in clinical development.
Side Effects & Safety.
In clinical trials, elamipretide has demonstrated a generally favorable safety profile. Injection site reactions are the most common adverse event. Some patients experienced mild gastrointestinal symptoms. No serious organ toxicity or dose-limiting effects were identified in Phase 1/2 trials. The targeted delivery to mitochondria means lower systemic exposure compared to untargeted compounds. However, as an investigational drug, the complete long-term safety profile is still being established through ongoing clinical trials.
Legal Status & Access.
SS-31/elamipretide is an investigational drug that has not received FDA approval. It has received Rare Pediatric Disease Designation and Fast Track Designation for Barth syndrome. Available from select research peptide suppliers for laboratory investigation.